Cullinan Therapeutics, Inc.
CGEM- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001789972
In the last 90 days, Cullinan Therapeutics, Inc. insiders filed 0 open-market purchases and 3 sales; 183 institutions reported holding it in 13F filings for Q2 2026, worth $1.30B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Cullinan Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 3 filings
- 1 insider, $922.9K in total
- Insiders trading
- 1
- Net value
- −$922.9K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Cullinan Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Michaelson Jennifer | Chief Scientific Officer | 158,844 | Sep 10, 2026 | 15 |
| Sumer Jacquelyn L | Chief Legal Officer | 130,559 | Jul 2, 2026 | 5 |
| Fenton Mary Kay | Chief Financial Officer | 127,921 | Jul 2, 2026 | 4 |
| Thistle Mary | Director | – | Jun 18, 2026 | 1 |
| Allen Andrew R | Director | – | Jun 18, 2026 | 1 |
| Webster Stephen W | Director | – | Jun 18, 2026 | 1 |
| Rosenberg Anthony | Director | – | Jun 18, 2026 | 1 |
| Meek David D. | Director | – | Jun 18, 2026 | 1 |
| Doyle Mittie | Director | – | Jun 18, 2026 | 1 |
| Ahmed Nadim | President and CEO | 390,803 | Feb 25, 2026 | 4 |
| Jones Jeffrey Alan | Chief Medical Officer | 159,968 | Feb 25, 2026 | 4 |
| Savill Corrine | Chief Business Officer | 240,990 | Feb 19, 2026 | 1 |
| Nichols Weston | 10% Owner | 8,963,500Indirect | Oct 30, 2025 | 3 |
| Lynx1 Capital Management LP | 10% Owner | 8,963,500Indirect | Oct 30, 2025 | 3 |
| Martin Anne-Marie | Director | – | Jun 16, 2025 | 0 |
| Ryan David P. | Director | – | Jun 16, 2025 | 0 |
| Ebeling Thomas | Director | 186,653 | Jun 11, 2024 | 0 |
| Trigilio Jeffrey | Chief Financial Officer | 133,919 | Feb 23, 2024 | 0 |
| Baeuerle Patrick | Chief Scientific Officer | 76,000 | Feb 21, 2023 | 0 |
| Biotechnology Value Fund L P | Other: See Explanation of Responses | 64,161 | Jan 19, 2023 | 0 |
| BVF Partners L P | 10% Owner | 64,161 | Jan 19, 2023 | 0 |
| BVF Inc | 10% Owner | 64,161 | Jan 19, 2023 | 0 |
| Biotechnology Value Fund II LP | Other: See Explanation of Responses | 64,161 | Jan 19, 2023 | 0 |
| Lampert Mark N | 10% Owner | 64,161 | Jan 19, 2023 | 0 |
| Biotechnology Value Trading Fund OS LP | Other: See Explanation of Responses | 64,161 | Jan 19, 2023 | 0 |
| BVF Partners OS Ltd. | Other: See Explanation of Responses | 64,161 | Jan 19, 2023 | 0 |
| BVF I GP LLC | Other: See Explanation of Responses | 64,161 | Jan 19, 2023 | 0 |
| BVF II GP LLC | Other: See Explanation of Responses | 64,161 | Jan 19, 2023 | 0 |
| BVF GP Holdings LLC | 10% Owner | 64,161 | Jan 19, 2023 | 0 |
| Jovan-Embiricos Morana | 10% Owner | 1,255,963 | Aug 4, 2022 | 0 |
| F2 Vision SCS | 10% Owner | 1,255,963 | Aug 4, 2022 | 0 |
| F2 Bioscience I 2017 Ltd | 10% Owner | 537,392 | Jun 23, 2022 | 0 |
| Gadicke Ansbert | Director | 7,648,268Indirect | Jun 23, 2022 | 0 |
| Keane Raymond T | Chief Legal Officer | 24,124 | Feb 15, 2022 | 0 |
| Zawel Leigh | See Remarks | 69,785 | Feb 15, 2022 | 0 |
| MPM BioImpact LLC | 10% Owner | 7,648,268 | Sep 20, 2021 | 0 |
| UBS Oncology Impact Fund L.P. | 10% Owner | 7,648,268 | Sep 20, 2021 | 0 |
| Oncology Impact Fund (Cayman) Management L.P. | 10% Owner | 7,648,268 | Sep 20, 2021 | 0 |
| MPM Oncology Impact Management GP LLC | 10% Owner | 7,805,483 | Aug 25, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 12, 2021 (view filing) | Oct 7 | 5 days | Zawel LeighSee Remarks | SSale | −1.08K | $25.00 | −$27.0K | −1.9%56.9K after | |
| Sep 21, 2021 (view filing) | Sep 20 | 1 day | Michaelson JenniferSee Remarks | SSale | −4.00K | $24.51 | −$98.0K | −14.9%22.9K after | 2 lots |
| Sep 21, 2021 (view filing) | Sep 20 | 1 day | Zawel LeighSee Remarks | SSale | −7.47K | $25.16 | −$187.9K | −11.4%57.9K after | |
| Sep 20, 2021 (view filing)5:31 PM ET | Sep 16 | 4 days | MPM BioImpact LLC and 2 others10% Owner | SSale | −3.12K | $29.06 | −$90.8K | 0.0%7.65M after | Duplicate filing |
| Sep 20, 2021 (view filing) | Sep 16 | 4 days | Gadicke AnsbertDirector, 10% Owner | SSale | −432 | $29.06 | −$12.6K | −0.2%244.6K after | |
| Sep 20, 2021 (view filing) | Sep 16 | 4 days | Gadicke AnsbertDirector, 10% Owner | SSale | −3.12K | $29.06 | −$90.8K | 0.0%7.65M after | |
| Sep 16, 2021 (view filing)4:45 PM ET | Sep 14-15 | 2 days | MPM BioImpact LLC and 2 others10% Owner | SSale | −13.5K | $29.17 | −$394.6K | −0.2%7.65M after | 2 lotsDuplicate filing |
| Sep 16, 2021 (view filing) | Sep 14-15 | 2 days | Gadicke AnsbertDirector, 10% Owner | SSale | −1.87K | $29.17 | −$54.5K | −0.8%245.0K after | 2 lots |
| Sep 16, 2021 (view filing) | Sep 14-15 | 2 days | Gadicke AnsbertDirector, 10% Owner | SSale | −13.5K | $29.17 | −$394.6K | −0.2%7.65M after | 2 lots |
| Sep 13, 2021 (view filing)6:24 PM ET | Sep 9-13 | 4 days | MPM BioImpact LLC and 2 others10% Owner | SSale | −23.3K | $29.23 | −$679.7K | −0.3%7.66M after | 3 lotsDuplicate filing |
| Sep 13, 2021 (view filing) | Sep 9-13 | 4 days | Gadicke AnsbertDirector, 10% Owner | SSale | −3.21K | $29.23 | −$94.0K | −1.3%246.9K after | 3 lots |
| Sep 13, 2021 (view filing) | Sep 9-13 | 4 days | Gadicke AnsbertDirector, 10% Owner | SSale | −23.3K | $29.23 | −$679.7K | −0.3%7.66M after | 3 lots |
| Sep 9, 2021 (view filing) | Sep 8 | 1 day | Trigilio JeffreyChief Financial Officer | SSale | −15.0K | $28.48 | −$427.2K | −87.0%2.25K after | 2 lots |
| Sep 9, 2021 (view filing) | Sep 8 | 1 day | Baeuerle PatrickSee Remarks | SSale | −11.0K | $28.45 | −$312.9K | −100.0%0 after | |
| Sep 8, 2021 (view filing)6:20 PM ET | Sep 3-8 | 5 days | MPM BioImpact LLC and 2 others10% Owner | SSale | −48.6K | $29.20 | −$1.42M | −0.6%7.69M after | 3 lotsDuplicate filing |
| Sep 8, 2021 (view filing) | Sep 3-8 | 5 days | Gadicke AnsbertDirector, 10% Owner | SSale | −6.72K | $29.20 | −$196.4K | −2.6%250.1K after | 3 lots |
| Sep 8, 2021 (view filing) | Sep 3-8 | 5 days | Gadicke AnsbertDirector, 10% Owner | SSale | −48.6K | $29.20 | −$1.42M | −0.6%7.69M after | 3 lots |
| Sep 8, 2021 (view filing) | Sep 7 | 1 day | Zawel LeighSee Remarks | SSale | −28.1K | $28.95 | −$814.0K | −30.1%65.4K after | |
| Sep 2, 2021 (view filing)5:26 PM ET | Aug 31-Sep 2 | 2 days | MPM BioImpact LLC and 2 others10% Owner | SSale | −24.3K | $29.50 | −$717.2K | −0.3%7.74M after | 4 lotsDuplicate filing |
| Sep 2, 2021 (view filing) | Aug 31-Sep 2 | 2 days | Gadicke AnsbertDirector, 10% Owner | SSale | −3.36K | $29.50 | −$99.1K | −1.3%256.8K after | 4 lots |
| Sep 2, 2021 (view filing) | Aug 31-Sep 2 | 2 days | Gadicke AnsbertDirector, 10% Owner | SSale | −24.3K | $29.50 | −$717.2K | −0.3%7.74M after | 4 lots |
| Aug 31, 2021 (view filing)4:47 PM ET | Aug 27-30 | 4 days | MPM BioImpact LLC and 2 others10% Owner | SSale | −44.4K | $29.24 | −$1.30M | −0.6%7.76M after | 2 lotsDuplicate filing |
| Aug 31, 2021 (view filing) | Aug 27-30 | 4 days | Gadicke AnsbertDirector, 10% Owner | SSale | −6.13K | $29.24 | −$179.3K | −2.3%260.2K after | 2 lots |
| Aug 31, 2021 (view filing) | Aug 27-30 | 4 days | Gadicke AnsbertDirector, 10% Owner | SSale | −44.4K | $29.24 | −$1.30M | −0.6%7.76M after | 2 lots |
| Aug 26, 2021 (view filing) | Aug 9-10 | 17 days | Zawel LeighSee Remarks | SSale | −28.1K | $26.77 | −$752.9K | −18.8%121.6K after | Amended5 lots |
| Aug 26, 2021 (view filing) | Aug 18 | 8 days | Michaelson JenniferSee Remarks | SSale | −4.00K | $27.66 | −$110.6K | −14.9%22.9K after | Amended2 lots |
| Aug 26, 2021 (view filing) | Aug 23 | 3 days | Zawel LeighSee Remarks | SSale | −28.1K | $29.00 | −$815.4K | −23.1%93.5K after | Amended |
| Aug 26, 2021 (view filing) | Aug 10 | 16 daysLate | Baeuerle PatrickSee Remarks | SSale | −11.0K | $27.00 | −$297.0K | −100.0%0 after | |
| Aug 25, 2021 (view filing)7:42 PM ET | Aug 23-25 | 2 days | MPM BioImpact LLC and 3 others10% Owner | SSale | −105.9K | $29.29 | −$3.10M | −1.3%7.81M after | 3 lots |
| Aug 25, 2021 (view filing) | Aug 23-25 | 2 days | Gadicke AnsbertDirector, 10% Owner | SSale | −14.6K | $29.29 | −$428.7K | −5.2%266.3K after | 3 lots |
| Aug 25, 2021 (view filing) | Aug 23-25 | 2 days | Gadicke AnsbertDirector, 10% Owner | SSale | −106.0K | $29.29 | −$3.10M | −1.3%7.81M after | 3 lots |
| Aug 12, 2021 (view filing)4:55 PM ET | Aug 11 | 1 day | MPM BioImpact LLC and 3 others10% Owner | SSale | −2.51K | $29.05 | −$72.9K | 0.0%7.91M after | Duplicate filing |
| Aug 12, 2021 (view filing) | Aug 11 | 1 day | Gadicke AnsbertDirector, 10% Owner | SSale | −347 | $29.05 | −$10.1K | −0.1%280.9K after | |
| Aug 12, 2021 (view filing) | Aug 11 | 1 day | Gadicke AnsbertDirector, 10% Owner | SSale | −2.51K | $29.05 | −$72.9K | 0.0%7.91M after |